Litmeier, Simon http://orcid.org/0000-0003-3682-133X
Meinel, Thomas R.
von Rennenberg, Regina
Kniepert, Joachim U.
Audebert, Heinrich J.
Endres, Matthias
Jung, Simon
Scheitz, Jan F.
Nolte, Christian H.
Funding for this research was provided by:
Schweizerische Herzstiftung (Grant FF19014)
Charité - Universitätsmedizin Berlin
Article History
Received: 20 December 2021
Revised: 28 January 2022
Accepted: 29 January 2022
First Online: 19 February 2022
Declarations
:
: TM was supported by the Swiss Heart Foundation (Grant FF19014). ME reports grants from Bayer and fees paid to the Charité from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. CHN received research grants from German Ministry of Research and Education, German Center for Neurodegenerative Diseases, German Center for cardiovascular Research. He received speaker and/or consultation fees from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Pfizer Pharma, Alexion, Abbott and W.L. Gore and Associates, all outside the submitted work. JFS reports speaker fees from AstraZeneca outside the submitted work. No relevant conflicts of interest. Outside the submitted work: HJA reports receiving personal fees from Bayer Vital, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk, Pfizer, Daiichi Sankyo and Sanofi. On behalf of the other authors, the corresponding author states that there is no conflict of interest.
: In accordance with laws and regulations in the Federal State of Berlin, ethics committee approval and patient consent were not required in Berlin for this study as all data were obtained as part of clinical routine work up. In Bern, the registry and this analysis were both approved by the responsible ethics committee (KEK Bern 2019-01010). In accordance with Swiss law, patients who, after being informed about the collection of their biological data, refused to allow its use for research purposes were excluded from the analysis.